IV Flecainide Challenge Test

The Flecainide challenge Challenge is a diagnostic test where flecainide (medication for abnormal heart rhythm) is administered through an intravenous (IV) line under careful medical supervision. This test is used performed to detect the characteristic electrocardiogram (ECG) changes to that may diagnose indicate Brugada Syndrome, a genetic disease in the heart's electrical system. It involves the administration of a specialised medication through an intravenous (IV) line. 

Who is it for:

The Flecainide Challengeis test may be recommended if you: 

• Have a family history of Brugada syndrome
• Show ECG characteristics suggesting Brugada syndrome
• Have unexplained fainting episodes

Your cardiologist will assess your condition to determine if this test is suitable for you.

What to prepare

You will need to fast for at least 6 hours before the test. This means no food and or drinks are allowed.

What to expect 

Before the test:

• A nurse will call will you one day before the test to remind you about fasting and reporting instructions.
• If you are under 21 years old, you must will need to be accompanied by a parent or guardian. 

During the test:

• You will be admitted to a High Dependency or Intermediate Care area.
• An IV line will be inserted over your arm for blood collection and medication infusion.
• Heart monitors will be attached to monitor your vital signs.
• The medication will be given over about 10 minutes.
• Doctors and nurses will closely monitor you throughout the process.
• Multiple ECGs will be taken and there will be continuous monitoring for 4 hours after the medication. 

After the test:

• You will need to stay overnight for monitoring.
• A doctor will review you the next day and discuss your test results and next steps.

The Flecainide Challenge is a diagnostic test to check for Brugada Syndrome. Depending on the test results, you may either continue with regular monitoring or be referred to an electrophysiologist (heart rhythm specialist) for further evaluation.

For more information, kindly visit our Brugada Syndrome page.